DNA topoisomerase (combined with DNA intercalation mechanism) (None)

DNA intercalation/topoisomerase inhibition refers to a pharmacological mechanism where compounds, commonly used in cancer chemotherapy, both insert themselves between base pairs in the DNA helix (intercalation) and inhibit the activity of DNA topoisomerase enzymes, especially type I (Top1) and type II (Top2). Intercalating agents distort the DNA structure, interfering with replication and transcription, while topoisomerase inhibitors block the catalytic cycle of these essential enzymes, stabilizing covalent DNA-enzyme intermediates, ultimately resulting in permanent DNA strand breaks and cell death. Many clinically important anti-cancer drugs—including the anthracyclines (such as doxorubicin), camptothecin derivatives (such as topotecan), and others—act through this dual mechanism. These agents are highly effective but carry significant risks including myelosuppression, cardiotoxicity, and DNA damage-related secondary cancers. In summary, "DNA intercalation/topoisomerase inhibition" is not a specific target but a description of a dual-action mechanism involving enzyme (topoisomerase) inhibition and DNA structural interference. For structured data, these components should be split or mapped to the canonical targets: DNA topoisomerase I or II.

Other names

DNA topoisomerase I (Top1)DNA topoisomerase II (Top2, sometimes Topo IIα or Topo IIβ)Topoisomerase I/IITopoisomerase poisons (as a drug class acting via both intercalation and enzyme inhibition)DNA-intercalating agents

Intercalation between DNA base pairs, causing DNA distortion and blocking transcription/replication. Stabilization of DNA-topoisomerase covalent complexes, preventing DNA religation and causing DNA strand breaks. Trapping of enzyme-DNA intermediates, referred to as "interfacial inhibition".